Author

Vladimir Chistyakov

Observed names: V. S. Chistiakov, V. S. Chistyakov, Vladimir S. Chistyakov

Institution: BIOCAD (Russia)

Observed institutions: First Pavlov State Medical University of St. Petersburg, BIOCAD (Russia)

ORCID: 0000-0003-2315-7791

Observed ORCID: 0000-0003-2315-7791

OpenAlex ID: A5059799395

Nicotine exposure throughout early development promotes nicotine self-administration in adolescent mice and induces long-lasting behavioural changes

2010 · Vladimir Chistyakov, Nadezhda Patkina, et al. · European Journal of Pharmacology · 36

Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine

2008 · Anne Tammimäki, Vladimir Chistyakov, et al. · European Journal of Pharmacology · 16

How to achieve chronic intravenous drug self-administration in mice

2005 · Vladimir S. Chistyakov, Vladimir L. Tsibulsky · Journal of Pharmacological and Toxicological Methods · 13

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

2024 · Lev Demidov, Galina Kharkevich, et al. · Frontiers in Oncology · 6

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

2023 · M. Yu. Fedyanin, A. V. Snegovoy, et al. · Safety and Risk of Pharmacotherapy · 6

Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

2025 · L. G. Zhukova, E. V. Artamonova, et al. · Medical alphabet

Works count: 6

Citation count: 77

H-index: 5

I10-index: 3